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Evaluation of lymphocyte apoptosis in 
patients with oral cancer
Objectives: To evaluate apoptotic levels of peripheral blood mononuclear 
cells (PBMCs) and apoptotic regulatory proteins (Bax and Bcl-2) in lymphocyte 
subsets of oral cancer (OC) patients and healthy controls (HC). Methodology: 
The percentage of apoptotic cells and lymphocyte counts were measured 
in the first cohort using PBMCs obtained from 23 OC patients and 6 HC. In 
the second cohort, (OC, 33; HC, 13), the mean fluorescence intensity (MFI) 
of Bax and Bcl-2 in CD19+ B, CD4+ T, CD8+ T, and CD16+56+ natural killer 
(NK) cells was determined via flow cytometry. Results: The percentage of 
apoptotic cells was higher in the PBMCs of OC patients than in HC patients, 
particularly in patients with stage IV cancer (p<0.05). However, lymphocyte 
counts were significantly lower in stage IV patients (p<0.05). NK CD19+ B 
and CD16+56+ cell counts were significantly lower in OC patients compared 
with HC patients (p<0.001 and p<0.01, respectively), but CD4+ T cells were 
interestingly significantly higher in OC patients (p<0.001). While Bax MFI 
was slightly higher, Bcl-2 MFI was significantly lower for all four lymphocyte 
subsets in OC samples, particularly in stage IV patients, when compared 
with HC. Consequently, Bax/Bcl-2 ratios showed an upward trend from HC 
to OC patients, particularly those in stage IV. We found similar trends in Bax 
and Bcl-2 MFI for tumor stage, tumor size, and lymph node involvement. 
Conclusions: The increased lymphocyte apoptosis in stage IV OC patients may 
be related to higher Bax levels and lower Bcl-2 levels. The Bax/Bcl-2 ratio in 
lymphocytes may be useful to determine the prognosis of OC patients, and 
could be considered a mean for supportive treatment in the future.
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Introduction
Oral cancer (OC) is a worldwide common type of 
malignancy.1 This cancer originates from the stratified 
squamous epithelium of the oral cavity and is called 
oral squamous cell carcinoma (OSCC).2 It is often 
diagnosed at advanced stages, entailing fatalities 
and low survival rates.3 During metastasis (stage 
IV), OSCC patients experience weakness and fatigue, 
are susceptible to infection, and commonly present 
leukopenia.4-6 Low lymphocyte counts (lymphopenia) 
may lead to a decrease in immune system’s ability to 
inhibit cancer development, promoting tumor growth 
and worsening prognosis.7
OC has an immune-escape mechanism. Malignant 
cells are associated with immune suppression, enabling 
cancer cells to evade the host’s immune surveillance.7,8 
The impaired function of the immune system might be 
directly associated with head and neck squamous cell 
carcinomas (HNSCC) growth and metastasis.8 It has 
also been reported that tumor cells can escape immune 
surveillance, inhibit immune function,9 and induce 
immunogenic cell death and lymphocyte apoptosis, 
changing lymphocyte homeostasis.7
Apoptosis is a form of programmed cell death 
that plays a critical role in normal development 
and homeostasis of adult tissues, including cell 
turnover, immune system development, embryonic 
development, and chemical-induced cell death.10,11 
Bcl-2-associated X (Bax), a pro-apoptotic protein, 
and B-cell lymphoma-2 (Bcl-2), an anti-apoptotic 
protein, are interrelated members of the Bcl-2 family 
proteins, associated with mechanisms that regulate 
the permeabilization of the mitochondrial outer 
membrane, a critical step of apoptosis.12 Defects 
in mechanisms of apoptosis are involved in tumor 
pathogenesis. Tumor cells can acquire resistance to 
apoptosis by Bax downregulation or mutation and Bcl-
2 upregulation. Bcl-2 and Bax expression is regulated 
by p53, a tumor suppressor gene.13 A previous study 
on cancer tissues found that the expression of Bax 
is strongly correlated with good clinical outcomes in 
HNSCC patients.14 Takemura and Noguchi15 (2002) 
corroborate with these results, reporting that patients 
with OSCC along with Bax expression had better 
prognosis than those without Bax expression. Some 
studies demonstrated that lower levels of Bcl-2 and 
higher levels of Bax are associated with overall clinical 
improvement in patients with OSCC.16,17
Under normal circumstances, apoptosis plays a 
key role within the immune system. A previous study 
observed lower levels of Bcl-2 in T cells of patients 
with HNSCC in comparison to healthy donors.18 Several 
studies, conducted in various conditions, reported 
that Bcl-2 and Bax are crucial for the survival and 
proliferation of several types of cells, such as CD4+ T, 
B, and natural killer (NK) cells.18-20
Our study focused on lymphocyte apoptosis, 
hypothesizing that lymphopenia in OC patients is 
associated with lymphocyte apoptosis. For that, we 
measured the levels of Bax and Bcl-2 in common 
lymphocyte subsets – CD19+ B, CD4+ T, CD8+ T, and 




This study was approved by the Institutional Review 
Board of the Faculty of Medicine of Chulalongkorn 
University (IRB No. 228/63), and was conducted 
according to the ethical principles established by the 
Declaration of Helsinki . All participants agreed to 
participate by signing a consent form before the start 
of the study.
Samples
In the first cohort, peripheral blood mononuclear 
cells (PBMCs) were collected for detecting apoptosis. 
In total, 25 samples were obtained from OC patients 
(stage I: 4; stage II: 1; stage III: 4; and stage IV: 
16) and 6 from HC (Table 1). In the second cohort, the 
levels of Bax and Bcl-2 apoptotic regulatory proteins 
were measured in 33 OC samples (stage I: 6; stage 
II: 3; stage III: 5; and stage IV: 19) and 13 HC 
samples (Table 1). All samples were collected from 
the Department of Otolaryngology, Head and Neck 
Surgery, Faculty of Medicine, Chulalongkorn University, 
Thailand. OSCC was confirmed via histopathological 
analysis, conducted by a pathologist (NK), and clinical 
staging was recorded using the tumor, node, and 
metastasis (TNM) staging system (PM, NT, and VK). 
PBMCs were isolated from heparinized blood using 
Ficoll–Paque density gradient centrifugation, following 
manufacturer’s instructions (Axis-Shield PoC AS, Oslo, 
Norway).
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Experiment Code Sex Age Staging Tumor size Lymph nodeinvolvement
Metastasis
HC1 F 58 - - - -
HC2 M 68 - - - -
HC3 F 55 - - - -
HC4 F 58 - - - -
HC5 F 58 - - - -
HC6 M 56 - - - -
OC1 M 64 I T1 N0 M0
OC2 M 57 I T1 N0 M0
OC3 M 33 I T1 N0 M0
OC4 M 78 I T1 N0 M0
OC5 F 43 II T2a Nx Mx
OC6 M 70 III T3 N1 M0
OC7 M 61 III T1 N1 M0
OC8 M 50 III T3 N0 M0
Percentage of lymphocytes and apoptotic cells OC9 M 68 III T3 N1 M0
OC10 F 43 IV T4a N1 M0
OC11 M 50 IV T4a N2 Mx
OC12 M 45 IV T4b N2 Mo
OC13 M 45 IV T4a N1 Mx
OC14 F 62 IV T4a N0 M0
OC15 F 26 IV T4a N3 Mx
OC16 F 60 IV T4a No Mx
OC17 F 62 IV T4b N0 Mx
OC18 F 53 IV T4a N0 Mx
OC19 M 80 IV T4 N2a Mx
OC20 M 54 IV T3 N2c Mx
OC21 M 71 IV T4b N0 M0
OC22 M 41 IV T2 N2 M0
OC23 M 76 IV T4a N2b M1
OC24 M 59 IV T2 N0 M1
OC25 M 45 IV T4a N2b M0
HC7 M 48 - - - -
HC8 F 52 - - - -
HC9 F 58 - - - -
HC10 M 68 - - - -
HC11 F 55 - - - -
HC12 F 58 - - - -
HC13 F 58 - - - -
HC14 M 56 - - - -
HC15 M 56 - - - -
HC16 M 23 - - - -
HC17 F 48 - - - -
HC18 M 57 - - - -
HC19 F 22 - - - -
OC26 M 65 I T1 N0 M0
OC27 M 59 I T1 N0 M0
OC28 M 40 I T1 N0 M0
OC29 F 61 I T1 N0 M0
OC30 M 75 I T1 N0 M0
OC31 M 74 I T1 N0 M0
OC32 F 45 II T2a Nx Mx
OC33 F 80 II T2 N0 M0
OC34 F 55 II T2 N0 M0
MFI of Bax and Bcl-2 OC35 M 63 III T3 N1 M0
OC36 M 61 III T1 N1 M0
OC37 M 52 III T3 N0 M0
OC38 M 59 III T3 N1 M0
OC39 M 65 III T3 N1 M0
OC40 F 40 IV T4a N1 M0
OC41 M 58 IV T4a N2 Mx
OC42 M 46 IV T4b N2 Mo
Table 1- Detailed data of samples in cohorts 1 and 2
Continued on the next page
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Apoptosis of PBMCs and lymphocyte count
PBMCs and gated lymphocytes were used to 
analyze data on apoptosis. The first cohort investigated 
lymphocyte count and the presence of apoptosis in 
samples from OC patients and HC. One million cells 
were stained with Annexin V Alexa Fluor 488 and 
propidium iodide (Biolegend, San Diego, CA, USA) for 
30 min at room temperature. Fluorescence-activated 
cell sorting (FACS) buffer was added to the cells for 
quantifying cell types via flow cytometry (LSRII, BD 
biosciences, CA, USA). Frequencies of lymphocytes 
were gated from forward scatter FCS and side scatter 
(SSC). Data were analyzed using the FlowJo program 
(Ashland, OR, USA).
Immune cell subsets with Bax and Bcl-2 
measurements
The second cohort categorized PBMCs into four 
types of immune cells based on cell-surface markers, 
as follows: CD19+ B, CD4+ T, CD8+ T, and CD16+CD56+ 
NK. The mean fluorescence intensities (MFI) of Bax and 
Bcl-2 were measured within these lymphocyte subsets. 
One million PBMCs were washed with phosphate-
buffered saline with 2% fetal bovine serum (FBS; FACS 
buffer) and stained with cell-surface markers for 20 
min at 4°C. The cell-surface markers contained PE-
DZ594-labeled anti-CD16 (clone 3G8) and anti-CD56 
(clone 5.1H11), PerCP-Cy5.5-labeled anti-CD19 (clone 
HIB19), PE-Cy7-labeled anti-CD3 (clone UCHT1), 
Alexa Fluor 700-labeled anti-CD8 (clone SK1), and 
APC-Cy7-labeled anti-CD4 (clone RPA-T4) (Biolegend, 
San Diego, CA, USA). After washing the cells twice 
in FACS buffer, they were fixed/permeabilized and 
stained in Alexa Fluor 488 anti-Bax (clone 2D2) and PE 
anti-Bcl-2 (clone 100) (Biolegend, San Diego, CA, USA) 
antibodies for 30 min at 4°C. Then, cells were again 
washed in FACS buffer, fixed in 2% paraformaldehyde 
(2% PFA), and analyzed via flow cytometry. Figure 1 
shows an example of the gating strategies used in 
flow cytometry for detecting Bax and Bcl-2 in CD19+ 
B, CD4+ T, CD8+ T, and CD16+56+ NK cells among 
HC (dash line), low-expression OC (black line), and 
high-expression OC (solid black line).
Statistical analysis
All statistical analyses were performed using SPSS 
v. 22 (SPSS Inc., Chicago, IL, USA). One-way analysis 
of variance (ANOVA) and unpaired t-test calculated 
significant differences in the first cohort. Kruskal–
Wallis test compared MFI among the groups in the 
second cohort. Pearson’s correlation coefficient (R) 
was used to assess correlations between apoptosis and 
different cell counts for each group. A p-value of less 
than 0.05 (<0.05) was considered statically significant.
Results
Percentage of lymphocytes and apoptotic 
PBMCs between OC patients and HC
Given the small sample of OC patients in the 
stages I, II, and III, we merged them into one group 
(OC stage I–III). The percentage of lymphocytes was 
higher in HC group, followed by OC stage I–III, and 
OC stage IV. The percentage of lymphocytes was 
significantly lower in OC stage IV than in HC samples 
(p<0.05; Figure 2A). However, the percentage of 
apoptotic cells gated from lymphocytes (Figure 2B) 
OC43 M 45 IV T4a N1 Mx
OC44 F 61 IV T4a N0 M0
OC45 F 26 IV T4a N3 Mx
OC46 F 54 IV T4a No Mx
OC47 F 63 IV T4b N0 Mx
OC48 F 59 IV T4a N0 Mx
OC49 M 74 IV T4 N2a Mx
MFI of Bax and Bcl-2 OC50 M 58 IV T3 N2c Mx
OC51 M 70 IV T4b N0 M0
OC52 M 46 IV T2 N2 M0
OC53 M 42 IV T4a N2 M0
OC54 M 40 IV T3 N2 M0
OC55 F 54 IV T4a N2b M0
OC56 M 76 IV T4a N2b M1
OC57 M 60 IV T2 N0 M1
OC58 M 47 IV T4a N2b M0
Continued from previous page
F = female, HC = healthy control, M = male, OC = oral cancer patient
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gradually increased from HC, to OC stage I–III, and 
OC stage IV. We found a significant difference between 
patients with OC stage IV and HC (p<0.05; Figure 2C), 
but no significant correlations between the percentage 
of lymphocytes and apoptotic cells within OC samples 
(R2=0.03; p=0.43; Figure 2D).
Percentage of lymphocyte subtypes and Bax/
Bcl-2 MFI and ratio between OC patients and 
HC
Figure 3A shows lymphocyte subsets. OC samples 
presented significantly higher CD4+ T cells (p<0.001) 
and significantly lower CD8+ T cells than HC. CD19+ B 
cells and CD16+56+ NK cells were significantly lower 
in OC than in HC samples (p<0.001 and p<0.01, 
respectively). Bax MFI of all four cell types was slightly 
higher in OC samples than in HC samples (Figure 3B). 
The two groups had similar Bcl-2 MFI levels (Figure 
3C). Bax/Bcl-2 ratio in CD19+ B, CD8+ T, and CD16+56+ 
NK cells were slightly higher in OC samples than in 
HC samples. The mean ± SD of OC vs. HC in CD19+ 
B cells were 2.42±1.08 vs. 1.95±0.41 (p=0.13) , 
in CD8+ T cells 1.96±0.85 vs. 1.66±0.52 (p=0.24), 
and in CD16+56+ NK cells  2.60±1.21 vs. 2.02±0.53 
(p=0.11)  (Figure 3D). 
Figure 1- Gating strategy of PBMCs via flow cytometry. Lymphocytes were gated from FSC and SSC based on size and granularity. CD3 
was used to identify T cells (CD3+) or non-T cells (CD3-). Staining with CD4 and CD8 antibodies against CD4 and CD8 T cells from CD3+ T 
cells and CD19 Ab for B cells and CD16/56 Ab for NK cells from CD3- T cells. Gated Bax and Bcl-2 expression of immune cells represented 
by mean fluorescence intensity (MFI). Bax and Bcl-2 expression in HC (dash line), low-expression OC (black line), and high-expression 
OC (solid black line)
Figure 2- Percentage of lymphocytes. (A), Gated lymphocytes (B) and apoptotic cells (C). Correlations observed between the percentage 
of lymphocytes and apoptotic cells in OC cells (D) among the PBMCs obtained from the OC patients and HC. *: p<0.05
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Percentage of lymphocyte subtypes and Bax/
Bcl-2 MFI and ratio between OC patients in 
stage I–III and stage IV 
The percentage of CD16+56+ NK cells was 
significantly lower in OC stage IV than in stage I–III 
(p<0.05; Figure 4A). Bax MFI of all four cell types 
was slightly higher in stage IV than in stage I–III 
samples (Figure 4B). Conversely, Bcl-2 MFI of all four 
cell types was significantly lower in stage IV (p<0.05; 
Figure 4C). Bax/Bcl-2 ratio in CD19+ B, CD4+ T, CD8+ 
T, and CD16+56+ NK cells had slightly higher levels in 
OC stage IV than in stage I-III samples. The mean ± 
SD of OC vs. HC in CD19+ B cells were 2.69±1.16 vs. 
2.01±0.82 (p=0.09), in CD4+ T 1.74±0.71 vs. 1.36 
Figure 3- Comparison between OC and HC samples. Frequency lymphocyte subsets (A) and MFI of Bax (B), Bcl-2**: P<0.01 (C), and 
Bax/Bcl-2 ratio (D) of the four lymphocyte cell types. *: p<0.05, **: p<0.01, ***: p<0.001
Figure 4- Comparison between stage I–III and stage IV OC samples. Frequency of lymphocyte subsets (A) and MFI of Bax (B), Bcl-2 (C), 
and Bax/Bcl-2 ratio (D) of the four lymphocyte cell types. *: p<0.05
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±0.56 (p=0.13), in CD8+ T 2.18±0.96 vs. 1.62±0.49 
(p=0.07), and in CD16+56+ NK cells 2.91±1.30 vs. 
2.12±0.92 (p=0.08) Figure 4D).  
Percentage of lymphocytes subtypes and Bax/
Bcl-2 MFI and ratio according to tumor size and 
lymph node metastasis
Regarding tumor size, the percentage of 
CD16+CD56+ NK cells was significantly lower in T4 
than in T1, T2, and T3 of OC samples (Figure 5A). Bax 
Figure 5- Comparison based on tumor size among T1, T2, T3, and T4 samples. Percentage of cells in the four lymphocyte subtypes (A). 
MFI of Bax, Bcl-2, and Bax/Bcl-2 of the four lymphocyte cell types (B-D).  *: p<0.05, **: p<0.01
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Figure 6- Comparison based on lymph node metastasis among N0, N1, N2, and N3 of samples. Percentage of cells in the four lymphocyte 
subtypes (A). MFI of Bax, Bcl-2, and Bax/Bcl-2 of the lymphocytes cell types (B–D)
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MFI of all four cell types gradually increased from T2 to 
T3 and T4 (Figure 5B). Bcl-2 MFI of all four cell types 
– particularly CD19+ B cells and CD8+ T cells – was 
considerably lower in T4 tumors (Figure 5C). Bax/Bcl-2 
ratio was significantly higher in T4 than in T2 tumors 
for all four cell types, mainly for CD19+ B cells and 
CD4+ T cells (p<0.01) and CD8+ T and CD16+56+ NK 
cells (p<0.05) (Figure 5D). Likewise, Bax/Bcl-2 ratio 
for CD8+ T and CD16+56+ NK cells was significantly 
higher in T4 than in T3 (Figure 5D; p < 0.05).
As for the number of metastatic lymph nodes, 
the percentage of CD4+ T cells and CD16+CD56+ NK 
cells was lower in N3, whereas for CD19+ B and CD8+ 
T-cells it was higher (Figure 6A). Both Bax and Bcl-2 
MFI were significantly different for all four cell types 
in N3 when compared with N0, N1, and N2 (Figure 
6B, 6C). Bax/Bcl-2 ratio in CD19+ B, CD4+ T, CD8+ T, 
and CD16+56+ NK cells had slightly higher levels in N3 
than N0, N1, and N2 (data not shown), but without 
statically significant difference. N3 p-value, when 
compared with N0, N1, and N2 for all four cell types, 
ranged from 0.48 to 0.99 (Figure 6D).  
Discussion
The immune system is an important defense 
mechanism to eliminate tumor cells, and the decrease 
of its functional response is intrinsically associated 
with cancer’s growth, metastasis, and its recurrence.21 
OC is an aggressive tumor, particularly in TNM stage 
IV – which corresponds to the metastatic stage.3 
Lymphocytes are an important type of immune cells 
that have been targeted for the treatment of OC22 
for being capable of recognizing cancer antigen and 
destroying cancer cells. In a recent study, we found 
that PBMCs in cancer patients may alter epigenetic 
regulation and gene expression as an effect of head 
and neck23 and breast cancer.24 Previous studies 
showed that lymphocyte apoptosis is related to 
weakness and tumor progression.8,9 Based on these 
findings, we hypothesized that cancer cells can alter 
the levels of proteins associated with lymphocyte 
function, including apoptosis.
In this study, we found significantly lower CD19+ 
B and CD16+56+ NK cell counts in OC patients than 
in HC. The percentage of CD16+56+ NK cells was 
significantly lower among OC stage IV patients. Ye, et 
al.25 (2017) reported that circulating tumor cells (often 
found in advanced-stage cancer) were associated with 
a decrease in the number of T lymphocyte subsets 
and NK cells in the peripheral blood of patients with 
advanced non-small cell lung cancer. As observed 
in patients with metastatic breast cancer, NK cells 
activity was also lower in patients with advanced-
stage colorectal and prostate cancer.26 NK cells are 
associated with innate immune system and contribute 
to the first-line defense against cancer and virus 
infection.27 These cells are responsible for producing 
tumor necrosis factor (TNF),  interferon gamma (IFNγ), 
interleukin-4 (IL-4), and interleukin-13 (IL-13)28 and 
exerting cytolytic activities against tumor cells.27 Many 
reports have shown that NK cells failure is associated 
with tumor growth.19 NK cells role in tumor immune 
surveillance comprises: inducing ligands activation, 
decreasing major histocompatibility complex (MHC) 
class I expression, retargeting via antibody-dependent 
cell-mediated cytotoxicity, and releasing granzyme, 
perforin, or cytokines to kill tumor cells.29 NK cells 
have acted as good prognostic markers in OC patients. 
Our results show that NK cells were reduced in OC 
patients in stage IV, T4, and N3 (advanced-stage), 
what suggests that increasing NK cell counts may be 
a useful alternative-supportive treatment in patients 
with OSCC.30,31
We also found that T helper (Th) cells were 
significantly higher in OC patients than in HC. This 
may be explained by the role of Th cells in anti-tumor 
response in promoting immune response, including the 
expansion of B cells and cytotoxic T cells, to eliminate 
tumor cells by secreting cytokines such as TNF and 
IFNγ.32 However, the percentage of Th cells was slightly 
lower in OC patients with N3 tumors, which may 
occur because these tumors were highly metastatic 
and may have escaped the T cell-mediated immune 
response mechanism by the adaptation of primary 
tumor antigens.33
Several studies on OC demonstrated that circulating 
peripheral blood lymphocytes, particularly T cells, are 
significantly lower during tumor progression.21 A 
study conducted by Reichert, et al.34 (2002) showed 
that T cells were present in lower number in the 
blood circulation and tumor microenvironment due 
to apoptosis in patients with head and neck cancer, 
indicating that apoptosis may play a crucial role in the 
development and progression of some cancers.
The anti-apoptotic Bcl-2 protein and pro-apoptotic 
Bax protein are involved in the intrinsic apoptosis 
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pathway and respond to cellular stresses, such as 
DNA damage, γ-irradiation, and oncogene activation.35 
During normal cell growth, Bax and Bcl-2 levels are 
balanced. Many studies show that an imbalance 
between Bax and Bcl-2, with increased levels of Bax 
and decreased levels of Bcl-2, affects lymphocytes 
proliferation and survival (such as Th, B, and NK cells) 
in patients with cancer.18,20
Our results show that Bax mean MFI was higher in 
all four lymphocyte types in OC patients, but Bcl-2 MFI 
of all cell types was significantly lower in OC stage IV. 
This may be explained by the influence of Bax in cancer 
development, and of Bcl-2 in its progression to stage 
IV. We also found a high Bax/Bcl-2 ratio in OC stage 
IV patients. These results corroborate those reported 
by Kim, et al.36 (2004) who found a high Bax/Bcl-2 
ratio in circulating CD8+ T cells of patients with HNSCC. 
Tumor size, lymph node involvement, and Bax/Bcl-2 
ratio were also higher in advance-stage tumors in our 
study, which may suggest that Bax/Bcl-2 ratio levels 
are associated with OSCC aggressiveness. However, 
further studies with a larger cohort are necessary to 
clarify this correlation.
The limited number of patients with OC stage I–III 
poses a limitation for our study. We suggest further 
studies to be conducted with a larger number of 
patients to confirm our findings. In conclusion, our 
results show that lymphocyte apoptosis and Bax/Bcl-2 
ratios were higher in patients with OC in stage 4, T4, 
and N3 tumors, indicating that they play an important 
role in cancer prognosis. These target molecules may 
prove useful for supportive treatment in the future.
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